Quark looks to Tel Aviv for $20 million IPO while BioLineRx heads stateside
This article was originally published in Scrip
Companies need to raise finance wherever they can get it, even if it means they cross each others paths. US siRNA technology firm Quark Pharmaceuticals has filed plans to float on the Tel Aviv stock exchange in a $20 million IPO, while, the Israeli biopharmaceutical company BioLineRx hopes to raise $31 million by listing on Nasdaq.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.